Centaurus Financial Inc. Boosts Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Centaurus Financial Inc. raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,103 shares of the medical equipment provider’s stock after buying an additional 357 shares during the period. Centaurus Financial Inc.’s holdings in Lantheus were worth $341,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in LNTH. Farallon Capital Management LLC increased its stake in shares of Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after purchasing an additional 1,269,900 shares in the last quarter. Swedbank AB bought a new stake in Lantheus during the first quarter valued at about $26,346,000. Point72 Asset Management L.P. purchased a new stake in Lantheus in the second quarter worth about $26,794,000. Massachusetts Financial Services Co. MA bought a new position in shares of Lantheus in the third quarter worth about $25,955,000. Finally, LSV Asset Management lifted its position in shares of Lantheus by 27.9% during the 2nd quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock valued at $51,462,000 after buying an additional 139,647 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. JMP Securities decreased their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Truist Financial restated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Stock Down 1.6 %

Shares of Lantheus stock opened at $89.53 on Wednesday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The business has a 50-day moving average price of $102.80 and a 200-day moving average price of $97.04. The firm has a market cap of $6.22 billion, a price-to-earnings ratio of 14.90 and a beta of 0.51.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.